Cornell male contraception research gains Falling Walls recognition
Bottom line
Version 1
Cornell veterinary geneticist Paula Cohen has been named a finalist in the Falling Walls Global Call for Science Breakthroughs 2026 for research aimed at developing a reversible, non-hormonal male contraceptive. Cornell says the work could lead to a long-acting product delivered by injection or patch and used continuously for two to four months. The recognition follows a 2026 proof-of-principle study from Cohen’s lab showing in mice that temporarily disrupting meiosis with the small-molecule inhibitor JQ1 halted sperm production and fertility, with recovery after treatment stopped. Falling Walls says finalists are selected after a shortlist process and will present at its Berlin summit, scheduled for November 6-9, 2026. (vet.cornell.edu)
Why it matters: For veterinary professionals, this is another example of how reproductive biology research inside a college of veterinary medicine can shape human health innovation as well as comparative medicine. Cohen’s lab has spent years positioning meiosis, and specifically testis-targeted, non-hormonal approaches, as a potential contraceptive pathway, backed by prior Gates Foundation support and a growing reproductive sciences infrastructure at Cornell. That kind of translational work can raise the profile of veterinary research in fertility, toxicology, drug delivery, and long-term reversibility, all areas with crossover relevance to animal and human medicine. (news.cornell.edu)
What to watch: Watch for whether the Falling Walls recognition brings new funding, collaborators, or follow-on studies that move Cohen’s platform beyond mouse proof-of-concept and toward a clinically viable compound. (falling-walls.com)
Key facts
- Researcher
- Paula Cohen
- Affiliation
- Cornell College of Veterinary Medicine
- Recognition
- Falling Walls Global Call for Science Breakthroughs 2026 finalist
- Goal
- Reversible, non-hormonal male contraceptive
- Delivery concept
- Injection or patch
- Duration
- Two to four months
- Study model
- Mice
- Proof-of-principle finding
- JQ1 temporarily disrupted meiosis, halted sperm production, and fertility recovered after treatment stopped
- Summit date
- November 6-9, 2026
Version 2
Paula Cohen, a professor of genetics at Cornell’s College of Veterinary Medicine, has been named a finalist in the Falling Walls Global Call for Science Breakthroughs 2026 for her work on reversible male contraception, giving international visibility to a research program housed inside a veterinary college but aimed at a longstanding gap in human reproductive medicine. Cornell says the goal is a long-acting, reversible, non-hormonal contraceptive for men that could eventually be delivered by injection or patch and used for two to four months at a time. (vet.cornell.edu)
The recognition builds on nearly a decade of work from Cohen’s lab to identify new contraceptive targets in meiosis rather than relying on hormone-based suppression. Cornell previously highlighted Gates Foundation support for the program in 2017 and again in 2020, framing the effort as an attempt to shift some of the contraceptive burden away from women while avoiding the systemic side effects often associated with hormonal approaches. Cohen also directs the Cornell Reproductive Sciences Center, which has helped position the university as a hub for fertility and contraception research. (news.cornell.edu)
The most important recent development came in April 2026, when Cohen’s team reported a proof-of-principle study in PNAS showing that transient inhibition of BRDT, a testis-specific chromatin reader, using JQ1 disrupted meiotic prophase I in male mice. According to the paper and Cornell’s summary, treated animals stopped producing mature sperm and were infertile during treatment, then recovered after the drug was withdrawn. The team characterized JQ1 as a research tool rather than a market-ready contraceptive candidate, noting that its value was in demonstrating that this stage of sperm development could be pharmacologically targeted in a reversible way. (pubmed.ncbi.nlm.nih.gov)
That distinction matters. Cornell’s own materials describe the program’s end goal as a practical non-hormonal product, but the current published evidence is still preclinical and based on a probe compound with known limitations. In other words, the summit recognition appears to honor the conceptual breakthrough, identifying meiosis as a tractable contraceptive target, rather than the arrival of a near-market therapy. Falling Walls’ process also supports that framing: finalists are selected as breakthrough candidates and the 2026 winners will be presented during the Berlin summit on November 9, with the broader event running November 6-9. (eurekalert.org)
Public-facing expert reaction located through Cornell channels has emphasized the field-level significance more than immediate commercialization. In Cornell’s April coverage, Cohen said her group is among the few pushing the idea that targets in the testis are a feasible way to stop sperm production. A recent review article on novel male contraceptives also places JQ1-style approaches within a broader, still-emerging non-hormonal pipeline, suggesting the field is expanding but remains early in translation. (news.cornell.edu)
Why it matters: For veterinary professionals, the story is less about a consumer contraceptive arriving soon and more about the strategic value of veterinary research environments in solving complex reproductive questions. Cohen’s lab sits at the intersection of genetics, reproductive biology, translational medicine, and comparative science, which is exactly where many clinically relevant discoveries begin. Work like this can strengthen the case for veterinary schools as engines of biomedical innovation, especially in areas such as fertility preservation, reproductive toxicology, gamete biology, and drug reversibility, where animal models and cross-species insight are central. (vet.cornell.edu)
There’s also a practical communications angle for the profession. Because the headline topic is male contraception, some audiences may miss that the science emerged from a veterinary college. For institutions and clinicians trying to explain the breadth of veterinary research to pet parents, policymakers, donors, and trainees, this kind of recognition is useful proof that veterinary academia contributes to major public health questions well beyond companion animal care. (vet.cornell.edu)
What to watch: The next milestones are likely to include additional mechanistic studies, refinement of drug candidates better suited than JQ1 for clinical development, and any new funding or partnerships catalyzed by the Falling Walls platform ahead of the November 2026 summit in Berlin. (eurekalert.org)